Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.62 |
| ▸ | GABRD | O14764 | 2/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.62 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.62 |
| ▸ | GABRE | P78334 | 2/20 | 0.62 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.62 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.62 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.62 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | LOX | P28300 | 1/20 | 0.55 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421806 | 1.00 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5610968 | 0.83 | LOXL2 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1886874 | 0.83 | RECQL (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17054221 | 0.81 | FFAR1 (0.64) | RECQLLOXLOXL3LOXL2FFAR1 | |
| SCHEMBL5737925 | 0.80 | RECQL (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4595837 | 0.80 | GABRP (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8268650 | 0.79 | RECQL (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2496843 | 0.79 | LOXL2 (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16332626 | 0.79 | RECQL (0.53) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6219254 | 0.78 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220340597-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-10-27 | — | — | US | disclosed |
| EP-4071147-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | Lg Chem, Ltd. (KR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114846013-A | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-02 | — | — | CN | disclosed |
| CN-101374843-A | Triazolopyridazines as tyrosine kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-25 | — | — | CN | disclosed |
| EP-1966214-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| EP-1805141-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2006043064-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340597-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, IL5, REN | GABRP 3818/4885GABRD 4574/4885GABRA1 2988/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | GABRP 1625/4885GABRD 4428/4885GABRA1 4297/4885 |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | GABRP 3474/4885GABRD 3429/4885GABRA1 2918/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | GABRP 1625/4885GABRD 4428/4885GABRA1 4297/4885 |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | DGAT2, DGAT1, PLAAT2 | GABRP 3141/4885GABRD 1398/4885GABRA1 2747/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | GABRP 2658/4885GABRD 1170/4885GABRA1 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.